Drug Trial Radar · NCT05842954
Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,720
Actual
Start
Mar 7, 2024
Primary completion
Jun 27, 2025
Study completion Nov 25, 2025
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- Collaborators
- Medicines for Malaria Venture (MMV), EDCTP, WANECAM
- First posted
- May 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 months, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aimed to confirm the efficacy, safety and tolerability of KLU156, a fixed dose combination of ganaplacide (KAF156) and a solid dispersion formulation of lumefantrine (lumefantrine-SDF), when administered once daily for three days in adults and children ≥ 10 kg of body weight suffering from uncomplicated P. falciparum malaria (with or without other Plasmodium spp. co-infection). In the extension phase, the safety, tolerability and efficacy of repeated treatment with KLU156 was assessed for a maximum of approximately 18 months in patients who did not experience early treatment failure (ETF), who did not experience any study treatment-related SAE (Serious Adverse Event) previously and who gave informed consent to participate in the Extension phase.
Conditions
- Uncomplicated Plasmodium Falciparum Malaria
Interventions
KLU156Drug
Oral use. KLU156 (400/480 mg) was the dose for patients with a bodyweight ≥ 35kg. Patients \< 35kg took a fraction of the dose according to weight group as defined in the protocol.
CoartemDrug
Oral use. Dosing was selected based on patient's body weight as per product's label.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Core Phase: PCR-corrected Adequate Clinical and Parasitological Response (ACPR) at Day 29Time frame: Day 29 (i.e., 28 days post-first dose administration)
- Core Phase: Uncorrected ACPR (US NDA Submission) at Day 29Time frame: Day 29
Locations
32 sites in 12 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Banfora, Burkina Faso
Novartis Investigative Site
Bobo-Dioulasso, Burkina Faso
Novartis Investigative Site
Nanoro, Burkina Faso
Novartis Investigative Site
Ouagadougou, Burkina Faso
Novartis Investigative Site
Sabou, Burkina Faso
Novartis Investigative Site
Abidjan, Côte d’Ivoire
Novartis Investigative Site
Agboville, Côte d’Ivoire
Novartis Investigative Site
Azaguié, Côte d’Ivoire
Novartis Investigative Site
Kimpese, Bas-Congo Province, Democratic Republic of the Congo
Novartis Investigative Site
Kisantu, Bas-Congo Province, Democratic Republic of the Congo
Novartis Investigative Site
Lubumbashi, Du Haut Katanga, Democratic Republic of the Congo
Novartis Investigative Site
Kenge, Kwango, Democratic Republic of the Congo
Novartis Investigative Site
Masi-Manimba, Kwilu, Democratic Republic of the Congo
Novartis Investigative Site
Lambaréné, Gabon
Novartis Investigative Site
Libreville, Gabon
Novartis Investigative Site
Kintampo, Ghana
Novartis Investigative Site
Navrango, Ghana
Novartis Investigative Site
Kombewa, Kenya
Novartis Investigative Site
Nairobi, Kenya
Novartis Investigative Site
Siaya, Kenya
Novartis Investigative Site
Sotouba, Mali
Novartis Investigative Site
Niamey, Niger
Novartis Investigative Site
Kigali, Rwanda
Novartis Investigative Site
Rubavu, Rwanda
Novartis Investigative Site
Rusizi, Rwanda
Novartis Investigative Site
Gicumbi, Northern Province, Rwanda
Novartis Investigative Site
Bagamoyo, Tanzania
Novartis Investigative Site
Korogwe Tanga, Tanzania
Novartis Investigative Site
Tanga, Tanzania
Novartis Investigative Site
Tororo, Uganda
Novartis Investigative Site
Ndola, Zambia
Novartis Investigative Site
Nchelenge, Luapula Province, Zambia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.